Michael Berk

发表

Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management

O. Plana-Ripoll, L. Williams, L. Schmaal, 2023, World psychiatry : official journal of the World Psychiatric Association.

Cognitive effects of adjunctive N-acetyl cysteine in psychosis

M. Berk, A. Bush, G. Malhi, 2016, Psychological Medicine.

ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis

M. Berk, P. McGorry, K. Allott, 2019, Trials.

A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice.

M. Berk, A. Bush, D. Copolov, 2009, Current medicinal chemistry.

Treatment of bipolar depression

M. Berk, G. Malhi, C. Davey, 2013, The Medical journal of Australia.

Age as a Predictor of Quit Attempts and Quit Success in Smoking Cessation – Findings from the ITC 4-Country Survey (2002-2014)

S. Dodd, O. Dean, M. Mohebbi, 2021 .

Seasonal influences on first-episode admission in affective and non-affective psychosis

M. Berk, P. McGorry, K. Hallam, 2006, Acta Neuropsychiatrica.

Current Pharmacotherapies for Smoking Cessation and Promising Emerging Drugs.

S. Dodd, Michael Berk, Jodie Harper, 2024, Current reviews in clinical and experimental pharmacology.

Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions – Improvement (CGI-S) scale in bipolar and major depressive disorder

M. Berk, S. Dodd, O. Dean, 2018, European Psychiatry.

International Congress on Schizophrenia Research

C. Tamminga, S. Schulz, S. Dodd, 2003, Schizophrenia Research.

'Mind and Body': a lifestyle programme for people on antipsychotic medication.

M. Berk, S. Dodd, Anthony Benson, 2009, Journal of evaluation in clinical practice.